SFT2D2 and prostate carcinoma: Prostate cancer cell proliferation, migration and invasion were reversed in the SFT2D2‐TBX19 overexpression group following ATP5F1A or ATP5F1B knockdown (Figure 7I–L and Figure S9B–E, Supporting Information).